RxDoctor Payments Data

Charles Presti, MD

Cardiovascular Disease · Fort Wayne, INNPI 1871585042

Payments from drug & device makers

$377in general payments, 2019–2025

Across 15 payments — averaging $25.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$86
  • Novartis$70
  • Johnson & Johnson$56
  • Novo Nordisk$43
  • Pfizer$42
  • E.r. Squibb & Sons, L.L.C.$38
  • plus $42 from 2 others

What the payments were for

  • Food & beverage$377100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$377 in reported general payments places this provider in the 20th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$55,392
Medicare patients
1,596
Services billed
1,966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban441$524,355
XareltoRivaroxaban105$148,625
Repatha SureclickEvolocumab57$71,103
EntrestoSacubitril/Valsartan37$66,755
MultaqDronedarone Hcl47$55,057
JardianceEmpagliflozin18$31,221
Praluent PenAlirocumab16$12,598
FarxigaDapagliflozin Propanediol13$7,598
Metoprolol Succinate586$7,221
Dabigatran EtexilateDabigatran Etexilate Mesylate13$3,425
Ezetimibe191$3,122
Atorvastatin Calcium491$3,090
Rosuvastatin Calcium346$2,650
Ranolazine ErRanolazine32$2,375
Carvedilol308$2,295

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$42$524,355441 claims
Johnson & JohnsonXarelto$56$148,625105 claims
NovartisEntresto$70$66,75537 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →